SCHEMBL2640819

SCHEMBL2640819

CN(Cc1ccc(-c2nnc(-c3cc(Br)cnc3N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)o2)cc1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 2/20 0.36
SMN1; SMN2 Q16637 5/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 3/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
MAPK14 Q16539 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
HPGD P15428 1/20 0.34
S1PR4 O95977 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34
PDPK1 O15530 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2640968 0.95 ATR (0.36) ATRSMN1; SMN2KDM4ELMNATP53
SCHEMBL12183897 0.94 ATR (0.36) ATRSMN1; SMN2KDM4ELMNATP53
SCHEMBL2641058 0.87 NPC1 (0.40) ATRSMN1; SMN2KDM4ELMNATP53
SCHEMBL2640799 0.85 NPC1 (0.38) ATRSMN1; SMN2KDM4ELMNATP53
SCHEMBL2640963 0.84 BACE1 (0.37) ATRKDM4ETP53RAB9ANPC1
SCHEMBL615316 0.84 ATR (0.43) ATRSMN1; SMN2KDM4ETP53RAB9A
SCHEMBL2640866 0.84 ATR (0.44) ATRSMN1; SMN2KDM4ELMNATP53
SCHEMBL2640841 0.83 ATR (0.38) ATRKDM4ENPC1MAPK14ALDH1A1
SCHEMBL2640906 0.80 ATR (0.36) ATRNPC1MAPK14S1PR1PDPK1
SCHEMBL2640952 0.80 ATR (0.45) ATRSMN1; SMN2KDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-08-27 US disclosed
US-9096584-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-08-04 US disclosed
EP-2569284-B1 2-AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2015-07-08 EP disclosed
EP-2569284-A1 2 -AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120177748-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
WO-2011143422-A1 2 -AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K20 ATR 1/4885SMN1; SMN2 1533/4885KDM4E 1807/4885
US-20120177748-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K20 ATR 1/4885SMN1; SMN2 1533/4885KDM4E 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.